<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>TIAN RUIXIANG Unveils unprecedented Asia-Pacific AI Healthcare Revolution: Strategic Partnership & Acquisition of Singapore's Top 3 Medical Leaders to Dominate AI-Driven Diagnostics Across Southeast Asia</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>TIAN RUIXIANG Unveils unprecedented Asia-Pacific AI Healthcare Revolution: Strategic Partnership & Acquisition of Singapore's Top 3 Medical Leaders to Dominate AI-Driven Diagnostics Across Southeast Asia</h1>

    <table>
      <tr><th>Ticker</th><td>TIRX</td></tr>
      <tr><th>Float</th><td>7.8 M</td></tr>
      <tr><th>IO</th><td>0.00%</td></tr>
      <tr><th>MC</th><td>9.3 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Tian Ruixiang Holdings Limited (NASDAQ: TIRX) issued a press release announcing it has entered strategic partnership and acquisition discussions with "Singapore's top three medical technology leaders" to integrate their AI diagnostic platforms into TIRX's insurance-clinic network across Southeast Asia and the broader Asia-Pacific. The company says the proposed transactions — subject to customary closing conditions, regulatory approvals, and shareholder consent — are expected to be finalized within 12 months. TIRX states the integration will enable high-accuracy predictive diagnostics (company claims 95%+), pan-Asia patient data and genomic integration, automation of routine workflows (company claims ~70%), and significant operational cost reductions (company claims >40%). The release contains forward-looking statements and invites investor/media inquiries.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Announced strategic partnership and acquisition discussions with Singapore's top three medical technology companies</li><li>Plans to integrate Singaporean AI diagnostic platforms into TIRX's insurance-clinic network across Asia-Pacific</li><li>Company-specified target timeline: expect to complete transactions within 12 months (subject to conditions)</li><li>Public company listed on NASDAQ (TIRX)</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Proposed transactions are subject to customary closing conditions, regulatory approvals, and shareholder consent</li><li>Key performance metrics cited (95%+ diagnostic accuracy, ~70% workflow automation, >40% cost reduction, unlocking 'trillions' in value) are forward-looking claims and not independently verified</li><li>Release contains forward-looking statements that may be affected by risks and uncertainties</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/d80fef2f-ef1f-4330-b717-c1384919265b" target="_blank">Original Article</a>
    </div>

    <div class="small">TIRX • TradersLink AI News</div>
  </div>
</body>
</html>